Gelteq Limited Inc (GELS) Enterprise Value to EBITDA Ratio

Public company logo of Gelteq (GELS)

Gelteq Limited (GELS) relies on outsourcing drug synthesis, fully delegating production to external contractors. Intellectual property monetization is based on patents for non-contact drug administration. This EV/EBITDA chart reflecting price action demonstrates a figure of 0.00. Stable product output is ensured by regular calibration of dosing systems and scheduled loading of contract capacities.

Gelteq - GELS Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Comprehensive metric breakdowns and analytics for gelteq.com (GELS)

- current price and projected stock value:
Stock Price Gelteq|GELS - Analyst Median Target
- market capitalization details:
Market Valuation GELS|GELS - Full Business Value
- business book valuation details:
Book Value per Share Gelteq|GELS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio gelteq.com|GELS - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Gelteq Limited|GELS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Gelteq|GELS - Company Aggregate Indebtedness|Debts to Book Capitalization GELS|GELS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Gelteq|Quick Liquidity gelteq.com
- financial results and valuation multiples details:
GELS - Final Profit|Expected Profit Gelteq Limited|GELS - Price to Earnings Ratio|Forward P/E Multiple Gelteq|GELS - PEG Multiple|EV/EBITDA Multiple GELS|GELS - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Gelteq|GELS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months gelteq.com|GELS - Earnings per share growth in current year|Expected earnings per share growth for next year Gelteq Limited
Fundamental valuation:Gelteq Limited Inc GELS
Manufactured products of Gelteq

To minimize risks when analyzing an issuer's leverage, it is necessary to evaluate the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. By analyzing the current EV/EBITDA trend of Gelteq Limited (GELS), an investor can determine how effectively the robotization of pharmaceutical lines reduces manual labor costs, ensuring cash flow stability for debt service.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Polyrizon Ltd (PLRZ)|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RPHM|Enterprise Value to EBITDA Ratio CSCI (COSCIENS Biopharma)